清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis

医学 羟甲唑啉 上睑下垂 随机对照试验 安慰剂 视力 临床终点 麻醉 外科 眼科 内科学 肾上腺素能受体 病理 受体 替代医学
作者
Charles B. Slonim,Shane Foster,Mark Jaros,Shane Kannarr,Michael S Korenfeld,Robert Smyth-Medina,David Wirta
出处
期刊:JAMA Ophthalmology [American Medical Association]
卷期号:138 (11): 1168-1168 被引量:16
标识
DOI:10.1001/jamaophthalmol.2020.3812
摘要

Importance

Treatment of acquired blepharoptosis (ptosis) is currently limited to surgical intervention.

Objective

To examine the efficacy and safety of oxymetazoline hydrochloride, 0.1%, ophthalmic solution (oxymetazoline, 0.1%) in participants with acquired ptosis.

Design, Setting, and Participants

This pooled analysis of 2 randomized, double-masked, placebo-controlled, multicenter phase 3 clinical trials included participants 9 years and older with acquired ptosis and superior visual field deficit. The 2 studies were conducted across 16 and 27 sites in the United States. Patients were enrolled from May 2015 to April 2019. Analyses for the individual trials were initiated after database lock and completed on September 6, 2017, and May 16, 2019. Pooled analysis was completed on August 25, 2019.

Interventions

Participants (randomized 2:1) received oxymetazoline, 0.1%, or vehicle, self-administered as a single drop per eye, once daily, for 42 days.

Main Outcomes and Measures

The primary efficacy end point was change from baseline in the number of points seen on the Leicester Peripheral Field Test, a test to detect superior visual field deficits due to ptosis, on days 1 (6 hours after instillation) and 14 (2 hours after instillation). The secondary end point, change from baseline in marginal reflex distance 1, was assessed at the same time points.

Results

In total, 304 participants were enrolled (mean [SD] age, 63.8 [13.8] years; 222 women [73%]). Overall, 97.5% (198 of 203) of participants receiving oxymetazoline, 0.1%, and 97.0% (98 of 101) of participants receiving vehicle completed the studies. Oxymetazoline, 0.1%, was associated with a significant increase in the mean (SD) number of points seen on the Leicester Peripheral Field Test vs vehicle (day 1: 5.9 [6.4] vs 1.8 [4.1]; mean difference, 4.07 [95% CI, 2.74-5.39];P < .001; day 14: 7.1 [5.9] vs 2.4 [5.5]; mean difference, 4.74 [95% CI, 3.43-6.04];P < .001). Oxymetazoline, 0.1%, also was associated with a significant increase in marginal reflex distance 1 from baseline (mean [SD]: day 1: 0.96 [0.89] mm vs 0.50 [0.81] mm; mean difference, 0.47 mm [95% CI, 0.27-0.67];P < .001; day 14: 1.16 [0.87] mm vs 0.50 [0.80] mm; mean difference, 0.67 mm [95% CI, 0.46-0.88];P < .001). Treatment-emergent adverse events (TEAEs) occurred in 31.0% (63 of 203) of participants receiving oxymetazoline, 0.1%, and 35.6% (36 of 101) of participants receiving vehicle. Among participants receiving oxymetazoline, 0.1%, with a TEAE, 81% (51 of 63) had a maximum TEAE intensity of mild, and 62% (39 of 63) had no TEAE suspected of being treatment related.

Conclusions and Relevance

Oxymetazoline, 0.1%, was associated with positive outcomes and was well tolerated in phase 3 trials after instillation at days 1 and 14, demonstrating its potential promise for the treatment of acquired ptosis, although further study is needed to elucidate the clinical relevance of these findings beyond 6 weeks.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
32秒前
董可以发布了新的文献求助10
38秒前
Orange应助董可以采纳,获得10
44秒前
飞翔的企鹅完成签到,获得积分10
57秒前
1分钟前
董可以发布了新的文献求助10
1分钟前
LYZSh发布了新的文献求助10
1分钟前
彭于晏应助董可以采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
LYZSh完成签到,获得积分10
1分钟前
鳗鱼飞松完成签到 ,获得积分20
1分钟前
widesky777完成签到 ,获得积分0
1分钟前
霜二完成签到 ,获得积分10
1分钟前
xiaofeixia完成签到 ,获得积分10
2分钟前
ys完成签到 ,获得积分10
2分钟前
grace完成签到,获得积分10
2分钟前
ll完成签到,获得积分20
3分钟前
852应助ll采纳,获得10
3分钟前
mojito完成签到 ,获得积分10
3分钟前
muriel完成签到,获得积分10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
奥利奥利奥完成签到 ,获得积分10
4分钟前
4分钟前
Dave发布了新的文献求助10
4分钟前
DouBo完成签到,获得积分10
4分钟前
Richardisme完成签到 ,获得积分10
4分钟前
qianchang完成签到,获得积分10
5分钟前
yuiop完成签到,获得积分10
5分钟前
liuyc完成签到 ,获得积分10
5分钟前
5分钟前
ll发布了新的文献求助10
5分钟前
糖果苏扬完成签到 ,获得积分10
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
zhang完成签到 ,获得积分10
5分钟前
蝴蝶完成签到 ,获得积分10
6分钟前
naczx完成签到,获得积分0
6分钟前
Dave发布了新的文献求助10
6分钟前
FashionBoy应助Dave采纳,获得10
7分钟前
yi完成签到,获得积分10
7分钟前
陈龙完成签到,获得积分10
7分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990543
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271057
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234